FdaApplication
NDA 208624
Identifiers
- fda_app_no: NDA208624
Properties
| Property | Value |
|---|---|
| applicant_name | ABBVIE INC |
| application_type | NDA |
| approval_date | 2016-07-22 |
Revenue by product
VIEKIRA XR
| Period | Revenue |
|---|---|
| Q1 2020 | $5.0M* |
| Q4 2019 | $4.0M* |
| Q3 2019 | $3.0M* |
| Q2 2019 | $4.0M* |
| Q1 2019 | $25.0M* |
| Q4 2018 | $43.0M* |
| Q3 2018 | $23.0M* |
| Q2 2018 | $41.0M* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VIEKIRA XR | DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE;ORAL |
1 product